SCHEMBL8184619

SCHEMBL8184619

CNN(CCN1CCOCC1)c1noc2cc(OC)ccc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 2/20 0.41
▸ HTR3A P46098 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ BCHE P06276 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3505500 0.86 ALDH1A1 (0.43) ALDH1A1BCHEACHECYP1A2KDM4E
SCHEMBL6957700 0.78 DRD3 (0.45) ALDH1A1GAAKDM4ETSHRSMN1; SMN2
SCHEMBL6959886 0.76 ALDH1A1 (0.53) CHRNA7HTR3AALDH1A1CYP1A2KDM4E
SCHEMBL3505067 0.75 ACHE (0.40) ALDH1A1BCHEACHEGAATDP1
SCHEMBL3507456 0.74 EPHX2 (0.41) ALDH1A1BCHEACHEGAATDP1
SCHEMBL8947062 0.72 ACHE (0.42) ALDH1A1BCHEACHEGAATDP1
SCHEMBL6951008 0.71 HRH3 (0.41) ALDH1A1BCHEACHE
SCHEMBL3504376 0.70 GRM4 (0.41) ALDH1A1ACHEGAALMNATSHR
SCHEMBL3504880 0.70 ALDH1A1 (0.56) ALDH1A1CYP1A2KDM4ELMNATSHR
SCHEMBL8375998 0.69 GAA (0.37) HTR3AALDH1A1BCHEACHEGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6046203-A USEFUL FOR THE TREATMENT OF VARIOUS MEMORY DYSFUNCTIONS CHARACTERIZED BY A DECREASED CHOLINERGIC FUNCTION SUCH AS ALZHEIMER'S DISEASE; ALSO INHIBIT MONOAMINE OXIDASE AND HENCE ARE USEFUL AS ANTIDEPRESSANTS AVENTIS PHARMACEUTICALS INC. (US) 2000-04-04 — — US disclosed
Send feedback